US 12226417
Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
granted A61KA61K31/513A61P
Quick answer
US patent 12226417 (Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists) held by Corcept Therapeutics Incorporated expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Corcept Therapeutics Incorporated
- Grant date
- Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K31/513, A61P, A61P1/16